A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2018 May 23

PMID 29783757

Citations 14

Authors

Hiroyuki Takabe

Zachary N Warnken

Yajie Zhang

Daniel A Davis

Hugh D C Smyth

John G Kuhn

Steve Weitman

Robert O Williams Iii

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the most common and lethal central nervous system tumor. Recently, atovaquone has shown inhibition of signal transducer and activator transcription 3, a promising target for GBM therapy. However, it is currently unable to achieve therapeutic drug concentrations in the brain with the currently reported and marketed formulations. The present study sought to explore the efficacy of atovaquone against GBM as well as develop a formulation of atovaquone that would improve oral bioavailability, resulting in higher amounts of drug delivered to the brain. Atovaquone was formulated as an amorphous solid dispersion using an optimized formulation containing a polymer and a spontaneously emulsifying component (SEC) with greatly improved wetting, disintegration, dispersibility, and dissolution properties. Atovaquone demonstrated cytotoxicity against GBM cell lines as well as provided a confirmed target for atovaquone brain concentrations in in vitro cell viability studies. This new formulation approach was then assessed in a proof-of-concept in vivo exposure study. Based on these results, the enhanced amorphous solid dispersion is promising for providing therapeutically effective brain levels of atovaquone for the treatment of GBM.

Citing Articles

Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme.

Bou-Gharios J, Noel G, Burckel H Cell Death Dis. 2024; 15(7):503.

PMID: 39003252 PMC: 11246422. DOI: 10.1038/s41419-024-06904-2.

Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.

Liu B, Zheng X, Li J, Yao P, Guo P, Liu W BMC Cancer. 2023; 23(1):1070.

PMID: 37932661 PMC: 10629062. DOI: 10.1186/s12885-023-11585-9.

Potential targets and treatments affect oxidative stress in gliomas: An overview of molecular mechanisms.

Liu S, Dong L, Shi W, Zheng Z, Liu Z, Meng L Front Pharmacol. 2022; 13:921070.

PMID: 35935861 PMC: 9355528. DOI: 10.3389/fphar.2022.921070.

Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.

Chalon S, Chughlay M, Abla N, Tchouatieu A, Haouala A, Hutter B Clin Pharmacol Ther. 2021; 111(4):867-877.

PMID: 34453327 PMC: 9291514. DOI: 10.1002/cpt.2404.

Repositioning of Antiparasitic Drugs for Tumor Treatment.

Li Y, Zheng Z, Liu Q, Lu X, Zhou D, Zhang J Front Oncol. 2021; 11:670804.

PMID: 33996598 PMC: 8117216. DOI: 10.3389/fonc.2021.670804.

References

Radloff P, Philipps J, Nkeyi M, Hutchinson D, Kremsner P . Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996; 347(9014):1511-4. DOI: 10.1016/s0140-6736(96)90671-6. View

Han T, Cho B, Choi E, Kim D, Song S, Paek S . Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. J Neurooncol. 2016; 130(1):89-98. DOI: 10.1007/s11060-016-2231-9. View

Douzinas E, Flevari K, Andrianakis I, Betrosian A . Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency. Scand J Infect Dis. 2009; 42(1):76-8. DOI: 10.3109/00365540903321606. View

cerpnjak K, Zvonar Pobirk A, Vrecer F, Gasperlin M . Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm. 2015; 495(1):336-346. DOI: 10.1016/j.ijpharm.2015.08.099. View

Ansari M, Arshad M, Hussain A, Ahmad Z . Improvement of solubility, dissolution and stability profile of artemether solid dispersions and self emulsified solid dispersions by solvent evaporation method. Pharm Dev Technol. 2016; 23(10):1007-1015. DOI: 10.1080/10837450.2016.1265554. View

Lu J, Shah S, Jo S, Majumdar S, Gryczke A, Kolter K . Investigation of phase diagrams and physical stability of drug-polymer solid dispersions. Pharm Dev Technol. 2014; 20(1):105-17. DOI: 10.3109/10837450.2014.949269. View

Villalva C, Martin-Lanneree S, Cortes U, Dkhissi F, Wager M, Le Corf A . STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?. Int J Cancer. 2010; 128(4):826-38. DOI: 10.1002/ijc.25416. View

Liu X, Zhou L, Zhang F . Reactive Melt Extrusion To Improve the Dissolution Performance and Physical Stability of Naproxen Amorphous Solid Dispersions. Mol Pharm. 2017; 14(3):658-673. DOI: 10.1021/acs.molpharmaceut.6b00960. View

Jensen K, Cseh O, Aman A, Weiss S, Luchman H . The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One. 2017; 12(12):e0189670. PMC: 5734728. DOI: 10.1371/journal.pone.0189670. View

10.

Zhang X, Zhang W, Cao W, Cheng G, Zhang Y . Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Exp Ther Med. 2012; 3(1):9-14. PMC: 3438851. DOI: 10.3892/etm.2011.367. View

11.

Friesen D, Shanker R, Crew M, Smithey D, Curatolo W, Nightingale J . Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008; 5(6):1003-19. DOI: 10.1021/mp8000793. View

12.

Sarode A, Wang P, Obara S, Worthen D . Supersaturation, nucleation, and crystal growth during single- and biphasic dissolution of amorphous solid dispersions: polymer effects and implications for oral bioavailability enhancement of poorly water soluble drugs. Eur J Pharm Biopharm. 2013; 86(3):351-60. DOI: 10.1016/j.ejpb.2013.10.005. View

13.

Sek L, Boyd B, Charman W, Porter C . Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. J Pharm Pharmacol. 2006; 58(6):809-20. DOI: 10.1211/jpp.58.6.0011. View

14.

Lin G, Chen Y, Lin Z, Wang X, Zheng Z, Chen L . STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. Int J Clin Exp Pathol. 2014; 7(6):3141-9. PMC: 4097241. View

15.

Dunay I, Heimesaat M, Bushrab F, Muller R, Stocker H, Arasteh K . Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother. 2004; 48(12):4848-54. PMC: 529229. DOI: 10.1128/AAC.48.12.4848-4854.2004. View

16.

Xiang M, Kim H, Ho V, Walker S, Bar-Natan M, Anahtar M . Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016; 128(14):1845-1853. PMC: 5054697. DOI: 10.1182/blood-2015-07-660506. View

17.

Luwor R, Stylli S, Kaye A . The role of Stat3 in glioblastoma multiforme. J Clin Neurosci. 2013; 20(7):907-11. DOI: 10.1016/j.jocn.2013.03.006. View

18.

Phillips D, Pygall S, Cooper V, Mann J . Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol. 2012; 64(11):1549-59. DOI: 10.1111/j.2042-7158.2012.01523.x. View

19.

Zhang Y, He L, Yue S, Huang Q, Zhang Y, Yang J . Characterization and evaluation of a self-microemulsifying drug delivery system containing tectorigenin, an isoflavone with low aqueous solubility and poor permeability. Drug Deliv. 2017; 24(1):632-640. PMC: 8241163. DOI: 10.1080/10717544.2017.1284946. View

20.

Shen J, Li R, Li G . Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo. 2009; 23(2):237-43. View